Market Cap
$1.9B
SRPT
Sarepta Therapeutics, Inc.
$17.25 ▼ -1.82%
Prev close $17.57Market cap$1.9B
ConsensusHold
12-mo target$21.73 (+26.0%)
▲ Neutral
Analyst conviction 4/10
High Impact Filing (7/10)33 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SRPT right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Hold (42%)
Inst. Holders
50 funds
Inst. Value
$1.7B
Inst. Activity
33 buys / 17 sells
Insider Activity
$0.00 buy / $123.2K sell
Insider Net $
-$123.2K
Social Sentiment
56° Neutral
SEC Reports
5
Price chart 30d -25.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: SRPT — 68.2% short (0.5M / 0.8M)
Short: 520,410 | Exempt: 15,457 | TRF Vol: 763,330 | Short Ratio: 68.2% | Off-exchange volume (dark
Sep 4, 2026 Insider
Rodino-Klapac Louise surrendered for taxes 21,423 shares
President, R&D and Tech Ops @ $22.22 ($476.0K)
Sep 4, 2026 Insider
Rothfuss Cristin surrendered for taxes 22,025 shares
EVP, General Counsel @ $22.22 ($489.4K)
Sep 4, 2026 Insider
Estepan Ian Michael surrendered for taxes 24,799 shares
Chief Operating Officer @ $22.22 ($551.0K)
Aug 12, 2026 Event
Jul 27, 2026 SEC ELEVIDYS
WARNING: ACUTE SERIOUS LIVER INJURY AND ACUTE LIVER FAILURE Acute serious liver injury, including li
Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is ret
8-K — Impact 3/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
18,994,958 shares ($341.3M)
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
8,916,090 shares ($160.2M)
Analyst ratings buy % +16.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
42% rate it Buy or better · 33 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Sep 28, 2026 | Needham | REITERATE | Underperform | 50% |
| Jul 9, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Jul 9, 2026 | Wolfe Research | UPGRADE | Outperform | 52% |
| Apr 16, 2026 | HC Wainwright & Co. | REITERATE | Sell | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 6 | 13 | 5 | 1 | 42% | |
| Aug 1, 2026 | 8 | 6 | 13 | 5 | 1 | 42% | |
| Jul 1, 2026 | 7 | 6 | 15 | 5 | 1 | 38% | |
| Jun 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| May 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| Apr 1, 2026 | 7 | 6 | 15 | 4 | 1 | 39% | |
| Mar 1, 2026 | 6 | 6 | 16 | 4 | 1 | 36% | |
| Feb 1, 2026 | 6 | 6 | 16 | 4 | 1 | 36% |
Price targets
Where 22 covering analysts think SRPT trades over the next 12 months.
$21.73 +26.0% upside Strong Buy
Current$17.25 Low$5.00 Median$20.00 High$38.00 22 analysts
$5.00$38.00
Analyst rating Hold· 2.8/5 as of Oct 2, 2026
Social media sentiment mood +25.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
56°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 0 bearish, 2 mixed, 3 neutral · avg impact 4.0/10.
NEUTRAL8-K3/10
Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Do
Jul 27, 2026
MIXEDINST-CLUSTER4/10
An institutional cluster in SRPT shows 6 buyers (adding $99M) and 5 sellers (reducing $102.8M) in Q3
Jun 11, 2026
NEUTRAL8-K3/10
Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 202
Jun 4, 2026
NEUTRALDEFA14A3/10
Sarepta Therapeutics filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting
Apr 24, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: SRPT — 68.2% short (0.5M / 0.8M)
Short: 520,410 | Exempt: 15,457 | TRF Vol: 763,330 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: SRPT — 66.6% short (0.4M / 0.6M)
Short: 429,096 | Exempt: 0 | TRF Vol: 644,104 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: SRPT — 66.5% short (0.6M / 0.9M)
Short: 576,966 | Exempt: 0 | TRF Vol: 867,507 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: SRPT — 66.9% short (0.5M / 0.7M)
Short: 479,255 | Exempt: 0 | TRF Vol: 716,354 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: SRPT — 68.6% short (0.6M / 0.9M)
Short: 628,817 | Exempt: 8,901 | TRF Vol: 915,989 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.37 | $-0.06–$1.13 | 386.4% | -11.4% | 4↑ 5↓ | $0.4B | 10 |
| Next Q | $0.12 | $-1.07–$1.08 | 103.3% | -30.1% | 2↑ 7↓ | $0.4B | 10 |
| Current FY | $4.34 | $2.88–$6.00 | 185.9% | -2.3% | 4↑ 7↓ | $1.8B | 10 |
| Next FY | $2.41 | $0.53–$4.79 | -44.4% | -6.2% | 6↑ 5↓ | $1.4B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.372 | — |
| 7d ago | $0.420 | -0.048 |
| 30d ago | $0.420 | -0.048 |
| 60d ago | $0.485 | -0.112 |
| 90d ago | $0.496 | -0.123 |
Institutional ownership
Which big funds own SRPT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.7B total value (97,195,348 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 33 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | $341.3M | 19.6% | ADD +28.7% |
| STATE STREET CORP | 8,916,090 | $160.2M | 9.2% | ADD +34.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8,377,470 | $150.5M | 8.6% | ADD +26.2% |
| TWO SIGMA INVESTMENTS, LP | 4,598,735 | $82.6M | 4.7% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,591,755 | $82.5M | 4.7% | — |
| FIRST TRUST ADVISORS LP | 4,365,951 | $78.5M | 4.5% | — |
| AQR CAPITAL MANAGEMENT LLC | 4,325,689 | $76.9M | 4.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,771,758 | $49.8M | 2.9% | ADD +39.4% |
| Erste Asset Management GmbH | 2,568,945 | $45.5M | 2.6% | — |
| MARSHALL WACE, LLP | 2,206,022 | $39.6M | 2.3% | DOUBLED +204.3% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 14,755,277 | 18,994,958 | +28.7% | $341.3M |
| STATE STREET CORP | ADD | 6,613,314 | 8,916,090 | +34.8% | $160.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 6,640,692 | 8,377,470 | +26.2% | $150.5M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 1,988,796 | 2,771,758 | +39.4% | $49.8M |
| MARSHALL WACE, LLP | DOUBLED | 725,068 | 2,206,022 | +204.3% | $39.6M |
| GOLDMAN SACHS GROUP INC | ADD | 1,078,252 | 2,042,501 | +89.4% | $36.7M |
| UBS Group AG | TRIM | 2,232,459 | 1,624,415 | -27.2% | $29.2M |
| NORTHERN TRUST CORP | ADD | 724,259 | 1,210,732 | +67.2% | $21.8M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,665,078 | 1,121,378 | -32.7% | $20.2M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 336,736 | 703,629 | +109.0% | $12.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 39 transactions. Net -$123.2K — $0.00 bought, $123.2K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Rodino-Klapac Louise | President, R&D and Tech Ops | TAX W/H | 21,423 | $22.22 | $476.0K |
| Sep 4, 2026 | Rothfuss Cristin | EVP, General Counsel | TAX W/H | 22,025 | $22.22 | $489.4K |
| Sep 4, 2026 | Estepan Ian Michael | Chief Operating Officer | TAX W/H | 24,799 | $22.22 | $551.0K |
| Sep 4, 2026 | Wong Ryan Ho-Yan | Chief Financial Officer | TAX W/H | 13,272 | $22.22 | $294.9K |
| Jul 28, 2026 | SEVERINO MICHAEL | Chief Executive Officer | AWARD | 756,104 | — | — |
| Jul 28, 2026 | SEVERINO MICHAEL | Chief Executive Officer | AWARD | 2,224,342 | — | — |
| Jun 4, 2026 | Chambers Michael Andrew | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Barry Richard | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Nicaise Claude | Director | AWARD | 16,875 | — | — |
| Jun 4, 2026 | Connelly Deirdre P | Director | AWARD | 16,875 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SRPT.
Shares short
25,434,681
Settlement Sep 15, 2026
Change vs prior
+3.3%
Semi-monthly cycle
Days to cover
8.0
At avg daily volume
Of shares outstanding
≈24.1%
Estimate — not % of float
All SRPT filing & press-release reports (5)
- 8-K reportJul 27, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 4, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportFeb 25, 2026